Bacterial proteins and peptides in cancer therapy
暂无分享,去创建一个
N. Bernardes | A. Chakrabarty | A. Fialho | Arsenio M Fialho | Ananda M Chakrabarty | Nuno Bernardes
[1] C. Beattie,et al. A first-in-class, first-in-human phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with metastatic refractory solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Shaji,et al. Protein and Peptide Drug Delivery: Oral Approaches , 2008, Indian journal of pharmaceutical sciences.
[3] R. Jenkins,et al. Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a peptide that mediates delivery to the brain. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[4] J. Reichert,et al. Future directions for peptide therapeutics development. , 2013, Drug discovery today.
[5] André F. Vieira,et al. P-cadherin role in normal breast development and cancer. , 2011, The International journal of developmental biology.
[6] A. Rehemtulla,et al. Destabilization of the Epidermal Growth Factor Receptor (EGFR) by a Peptide That Inhibits EGFR Binding to Heat Shock Protein 90 and Receptor Dimerization*♦ , 2013, The Journal of Biological Chemistry.
[7] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[8] S. Manna,et al. Glioblastoma Multiforme: Novel Therapeutic Approaches , 2012, ISRN neurology.
[9] A. Mehta,et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. , 2011, Blood.
[10] C. Beattie,et al. Noncationic peptides obtained from azurin preferentially enter cancer cells. , 2009, Cancer research.
[11] M. Wangpaichitr,et al. Arginine Deiminase and Cancer Therapy , 2010 .
[12] D. Schlaepfer,et al. Multiple connections link FAK to cell motility and invasion. , 2004, Current opinion in genetics & development.
[13] A. Duhme-Klair,et al. The background, discovery and clinical development of BCR-ABL inhibitors. , 2013, Drug discovery today.
[14] Neha Kohli,et al. Oral delivery of bioencapsulated proteins across blood-brain and blood-retinal barriers. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[15] D. Majumdar,et al. A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt , 2011, Angiogenesis.
[16] M. Bucciantini,et al. Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy , 2011, International journal of nanomedicine.
[17] E. Arbit,et al. Glucose-Reducing Effect of the ORMD-0801 Oral Insulin Preparation in Patients with Uncontrolled Type 1 Diabetes: A Pilot Study , 2013, PloS one.
[18] R. Verma,et al. Therapeutic potential of anticancer immunotoxins. , 2011, Drug discovery today.
[19] D. Schlaepfer,et al. Integrin-regulated FAK-Src signaling in normal and cancer cells. , 2006, Current opinion in cell biology.
[20] Arsenio M. Fialho,et al. The Role and Importance of Intellectual Property Generation and Protection in Drug Development , 2010 .
[21] A. Chakrabarty,et al. Overcoming drug resistance in multi-drug resistant cancers and microorganisms , 2012, Bioengineered.
[22] A. Chakrabarty,et al. Internalization of bacterial redox protein azurin in mammalian cells: entry domain and specificity , 2005, Cellular microbiology.
[23] E. Avizienyte,et al. Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. , 2005, Current opinion in cell biology.
[24] J. Guan,et al. Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis. , 2010, Cancer letters.
[25] A. Mercurio,et al. Neuropilin-2 regulates α6β1 integrin in the formation of focal adhesions and signaling , 2012, Journal of Cell Science.
[26] C. Beattie,et al. A 28-Amino-Acid Peptide Fragment of the Cupredoxin Azurin Prevents Carcinogen-Induced Mouse Mammary Lesions , 2010, Cancer Prevention Research.
[27] G. Kim,et al. The Bacterial Protein Azurin Enhances Sensitivity of Oral Squamous Carcinoma Cells to Anticancer Drugs , 2011, Yonsei medical journal.
[28] A. Chakrabarty,et al. Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth. , 2007, Biochemistry.
[29] R. A. Etten,et al. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition , 2007, Nature Reviews Cancer.
[30] Carlos L. Arteaga,et al. Treatment of HER2-positive breast cancer: current status and future perspectives , 2012, Nature Reviews Clinical Oncology.
[31] Sten Ohlson,et al. Designing transient binding drugs: a new concept for drug discovery. , 2008, Drug discovery today.
[32] H. Hua,et al. Matrix metalloproteinases in tumorigenesis: an evolving paradigm , 2011, Cellular and Molecular Life Sciences.
[33] G. Demetri,et al. Molecular basis for sunitinib efficacy and future clinical development , 2007, Nature Reviews Drug Discovery.
[34] David Zurakowski,et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib , 2007, The Lancet.
[35] A. Chakrabarty,et al. Promiscuous Anticancer Drugs from Pathogenic Bacteria: Rational Versus Intelligent Drug Design , 2010 .
[36] D. Majumdar,et al. A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells , 2009, Molecular Cancer Therapeutics.
[37] Ljiljana Paša-Tolić,et al. Identification of a Putative Protein Profile Associated with Tamoxifen Therapy Resistance in Breast Cancer*S⃞ , 2009, Molecular & Cellular Proteomics.
[38] E. Sauter,et al. Increased shedding of soluble fragments of P‐cadherin in nipple aspirate fluids from women with breast cancer , 2008, Cancer science.
[39] A. Chakrabarty,et al. Beyond host-pathogen interactions: microbial defense strategy in the host environment. , 2007, Current opinion in biotechnology.
[40] J. Bergh,et al. Hurdles in anticancer drug development from a regulatory perspective , 2012, Nature Reviews Clinical Oncology.
[41] M. Moore,et al. Advanced pancreatic carcinoma: current treatment and future challenges , 2010, Nature Reviews Clinical Oncology.
[42] Funda Meric-Bernstam,et al. Targeting the mTOR signaling network for cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Carmen Jerónimo,et al. P-Cadherin Overexpression Is an Indicator of Clinical Outcome in Invasive Breast Carcinomas and Is Associated with CDH3 Promoter Hypomethylation , 2005, Clinical Cancer Research.
[44] A. Chakrabarty,et al. Apoptosis or growth arrest: Modulation of tumor suppressor p53's specificity by bacterial redox protein azurin. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[45] Yunlei Zhang,et al. Escherichia coli Nissle 1917 Targets and Restrains Mouse B16 Melanoma and 4T1 Breast Tumors through Expression of Azurin Protein , 2012, Applied and Environmental Microbiology.
[46] A. Wolff,et al. Treatment of HER 2-positive Breast Cancer , 2015 .
[47] F. Milletti,et al. Cell-penetrating peptides: classes, origin, and current landscape. , 2012, Drug discovery today.
[48] Xin Huang,et al. Bacterial redox protein azurin induce apoptosis in human osteosarcoma U2OS cells. , 2005, Pharmacological research.
[49] W. McBride,et al. Small Azurin Derived Peptide Targets Ephrin Receptors for Radiotherapy , 2011, International Journal of Peptide Research and Therapeutics.
[50] N. Bernardes,et al. The Bacterial Protein Azurin Impairs Invasion and FAK/Src Signaling in P-Cadherin-Overexpressing Breast Cancer Cell Models , 2013, PloS one.
[51] A. Chakrabarty,et al. Patent controversies and court cases , 2012, Cancer biology & therapy.
[52] Manuel A. S. Santos,et al. High-throughput molecular profiling of a P-cadherin overexpressing breast cancer model reveals new targets for the anti-cancer bacterial protein azurin. , 2014, The international journal of biochemistry & cell biology.
[53] X. Zheng,et al. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. , 2011, Drug discovery today.
[54] D. Majumdar,et al. A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours , 2013, British Journal of Cancer.
[55] A. S. A. Don,et al. Recent clinical trials of mTOR-targeted cancer therapies. , 2011, Reviews on recent clinical trials.